N-terminal cyclization of a nonsulfated CCK analogue exhibits opioid antagonist activity in vitro
Lemcke, P.K.; Sugg, E.; Malarchik, M.; Lui, G.; Serra, M.; Yamamura, H.I.; Hruby, V.J.; Shook, J.E.; Burks, T.F.
Proceedings of the Western Pharmacology Society 30: 223-226
1987
ISSN/ISBN: 0083-8969 PMID: 3628282 Document Number: 291815
Document emailed within 1 workday
Related Documents
Mosberg, H.I.; Heyl, D.L.; Haaseth, R.C.; Omnaas, J.R.; Medzihradsky, F.; Smith, C.B. 1990: Cyclic dermorphin-like tetrapeptides with delta-opioid receptor selectivity. 3. Effect of residue 3 modification on in vitro opioid activity Molecular Pharmacology 38(6): 924-928Vartanian, G.S.; Agadzhanov, M.I.; Tadevosian, I.U.; Batikian, T.B. 1996: Catabolism of phosphoinositides after treatment with opioid agonist phenaridin and its antagonist in brain synaptosomes of albion rats in vitro Biulleten' Eksperimental'noi Biologii i Meditsiny 122(10): 405-406
Wire, W.S.; Pelton, J.T.; Kazmierski, W.; Hruby, V.J.; Burks, T.F.; Shook, J.E. 1987: Structure-activity analysis of five constrained somatostatin like peptides with opioid antagonist properties Proceedings of the Western Pharmacology Society 30: 237-241
Patacchini, R.; Quartara, L.; Rovero, P.; Goso, C.; Maggi, C.A. 1993: Role of C-terminal amidation on the biological activity of neurokinin A derivatives with agonist and antagonist properties Journal of Pharmacology and Experimental Therapeutics 264(1): 17-21
Spetea, M.; Asim, M.Faheem.; Noha, S.; Wolber, G.; Schmidhammer, H. 2013: Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening Current Pharmaceutical Design 19(42): 7362-7372
Cserpán, E.; Tryoen-Tóth, P.; Bajenaru, L.; Benyhe, S.; Maderspach, K. 1997: Differential expression of the K-2 opioid receptor protein under the effect of opioid agonists in embryonic chick neurons in vitro Neurobiology 5(2): 233-248
Zimmerman, D.M.; Leander, J.D.; Reel, J.K.; Hynes, M.D. 1987: Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands Journal of Pharmacology and Experimental Therapeutics 241(2): 374-378
Arakawa, K.; Akami, T.; Okamoto, M.; Akioka, K.; Nakai, I.; Oka, T.; Nagase, H. 1993: Immunosuppression by delta opioid receptor antagonist Transplantation Proceedings 25(1 Part 1): 738-740
Magalini, S.I.; Scrascia, E.; de Francisci, G. 1979: A simple antagonist in acute opioid poisoning: naloxone Minerva Anestesiologica 45(1-2): 71-75
Ko, T.C.; Bertram, M.F.; Prinz, R.A.; Castelli, M.; Djuricin, G.; Jacobs, H.K. 1992: Effect of somatostatin analogue and cholecystokinin receptor antagonist on bile-induced acute canine pancreatitis American Surgeon 58(4): 213-219
Lasta, S.; Fajloun, Z.; Mansuelle, P.; Sabatier, J.M.; Boudabous, A.; Sampieri, F. 2008: Chemical synthesis of lactococcin B and functional evaluation of the N-terminal domain using a truncated synthetic analogue Archives de l'Institut Pasteur de Tunis 85(1-4): 9-19
Bauer, G.; Birnbaum, U.; Höfler, P.; Heldin, C.H. 1985: EBV-inducing factor from platelets exhibits growth-promoting activity for NIH 3T3 cells EMBO Journal 4(8): 1957-1961
Kato, H. 2008: Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence Nihon Arukoru Yakubutsu Igakkai Zasshi 43(5): 697-704
Bot, G.; Blake, A.D.; Li, S.; Reisine, T. 1998: Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist Journal of Pharmacology and Experimental Therapeutics 284(1): 283-290
Rudnicka, W.; Foks, H.; Janowiec, M.; Zwolska-Kwiek, Z. 1986: Studies of pyrazine derivatives. XXI. Synthesis and tuberculostatic activity of 4-aryl-1-pyrazinoylthiosemicarbazides and the products of their cyclization to 1,2,4-triazole-3-thione derivatives Acta Poloniae Pharmaceutica 43(6): 523-528
Sangild, P.T.; Elnif, J. 1996: Intestinal hydrolytic activity in young mink (Mustela vison) develops slowly postnatally and exhibits late sensitivity to glucocorticoids Journal of Nutrition 126(9): 2061-2068
Eshet, R.; Silbergeld, A.; Kauli, R.; Lazar, L.; Laron, Z. 1994: GH and GHBP activity and not IGF-1 and its receptor activity express growth velocity reduction during treatment of central precocious puberty by a superactive GNRH analogue Israel Journal of Medical Sciences 30(8): 592-595
Hanlon, M.H.; Ferone, R.; Mullin, R.J.; Keith, B.R. 1990: In vivo and in vitro metabolism of 5-deazaacyclotetrahydrofolate, an acyclic tetrahydrofolate analogue Cancer Research 50(11): 3207-3211
Hirning, L.D.; Peterson, L.J.; Burks, T.F. 1985: Comparison of mu opioid agonists in vitro Proceedings of the Western Pharmacology Society 28: 111-113
Baumann, G.; Andersen, E.; Quesniaux, V.; Eberle, M.K. 1992: Cyclosporine and its analogue SDZ IMM 125 mediate very similar effects on T-cell activation--a comparative analysis in vitro Transplantation Proceedings 24(4 Suppl 2: 43-48